New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 5, 2012
10:38 EDTRHHBY, REGNCompounding linked to new round of contamination, NY Times says
A deadly meningitis outbreak is being linked to a steroid drug being contaminated by fungus at the New England Compounding Center, according to a New York Times report. The report noted that the center has a history of problems, including past FDA warnings cautioning it against opening sterile vials of Roche's (RHHBY) Avastin. The Fly notes that Regeneron Pharmaceuticals' (REGN) Eylea competes with Avastin as a treatment for Wet Macular Degeneration. Reference Link
News For RHHBY;REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
11:14 EDTRHHBYRoche unit announces collaboration pact with ImmunoGen
Ventana Medical Systems, a member of the Roche Group (RHHBY), announced it has entered into an agreement with ImmunoGen (IMGN) to collaborate on the development of biomarker assays and a companion diagnostic immunohistochemistry test for one or more of ImmunoGen's product candidates. Under this agreement, the companies have created an initial test for folate receptor alpha, or FRa, that is being used in early trials of IMGN853, ImmunoGen's FRa-targeting antibody-drug conjugate.
October 27, 2014
20:54 EDTRHHBYLeerink's major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
07:20 EDTRHHBYAmerican Association of Blood Banks to hold annual meeting
Subscribe for More Information
October 24, 2014
12:03 EDTRHHBYRoche reports CHMP recommends label update for Esbriet
Subscribe for More Information
08:04 EDTREGNRegeneron price target raised to $460 from $350 at Canaccord
Subscribe for More Information
October 21, 2014
07:15 EDTRHHBYFDA to hold workshop on breast cancer drug development
Subscribe for More Information
October 20, 2014
12:37 EDTRHHBYOn The Fly: Midday Wrap
Subscribe for More Information
07:19 EDTRHHBYIBC Life Sciences to hold a conference
Subscribe for More Information
07:16 EDTREGNAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
07:11 EDTRHHBYAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTRHHBY, REGNAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:06 EDTRHHBYNewLink announces worldwide license agreement for NLG919 development
Subscribe for More Information
07:04 EDTRHHBYRoche approval would be positive for TESARO, says Jefferies
Subscribe for More Information
07:02 EDTREGNRegeneron Sanofi begins dosing in Phase 3 study of dupilumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis, or AD, that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical program for dupilumab, is a randomized, double-blind, placebo-controlled, multi-national study with the primary objective of demonstrating the efficacy of dupilumab in adults with moderate to severe AD when administered concomitantly with topical corticosteroids through 16 weeks.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use